Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.49 USD
-0.01 (-2.60%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.51 +0.02 (3.85%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Enveric Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 40 |
Cost Of Goods | 0 | 0 | 0 | 0 | 32 |
Gross Profit | 0 | 0 | 0 | 0 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 27 | 65 | 6 | 14 |
Income After Depreciation & Amortization | -16 | -27 | -65 | -6 | -6 |
Non-Operating Income | -1 | 7 | 8 | -1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -17 | -20 | -56 | -7 | -5 |
Income Taxes | 0 | -1 | -7 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -17 | -18 | -49 | -7 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -17 | -18 | -49 | -7 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -20 | -25 | -5 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 8 | 39 | 0 | 2 |
Income After Depreciation & Amortization | -16 | -27 | -65 | -6 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.16 | 1.45 | 0.47 | 0.12 | 0.01 |
Diluted EPS Before Non-Recurring Items | -8.01 | -8.86 | -21.50 | -59.50 | -566.00 |
Diluted Net EPS (GAAP) | -8.09 | -13.00 | -103.50 | -59.50 | -566.00 |
Fiscal Year end for Enveric Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.90 | 2.48 | 2.38 | 3.45 | 5.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.90 | -2.48 | -2.38 | -3.45 | -5.76 |
Non-Operating Income | 0.02 | 0.02 | -1.03 | 0.63 | -0.60 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.88 | -2.46 | -3.41 | -2.82 | -6.36 |
Income Taxes | 0.00 | 0.00 | 0.04 | -0.01 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.88 | -2.46 | -3.45 | -2.81 | -6.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.88 | -2.46 | -3.44 | -2.82 | -6.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 7.59 | 4.00 | 2.35 | 2.17 | 2.11 |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.61 | -1.46 | -1.30 | -3.04 |
Diluted Net EPS (GAAP) | -0.25 | -0.61 | -1.44 | -1.30 | -3.04 |